introducing a new class of gene delivery
phage-derived particles (PDPs)
VISION
reimagining genomic medicines
gensaic's phage-derived particle (PDP) represents a new class of in-vivo gene delivery vehicles enabling tissue-specific targeting, massive cargo capacity, and efficient manufacturing.
tissue-specific delivery
PDP targeting is based on 2018 Nobel Prize winning research - phage-display. Leveraging this breakthrough technology, PDPs can be modularly designed to display high affinity targeting molecules on its coat for delivery to target tissues. Currently, we're developing PDPs that target the liver, lung, and central nervous system (CNS).
enormous cargo capacity
Traditional gene therapies rely on adeno-associated virus (AAV) vectors and are limited to 4.7 kb of genetic cargo. PDPs allow packaging of DNA up to 20 kb, enabling the packaging of >99% full-length human genes (cDNA) for precise expression and optimized native function.
re-doseable
gene therapy
Our PDPs are engineered from M13 phage, a natural resident of our microbiome. Billions of phages enter our bloodstream on a daily basis, lending M13 phage an immune-privileged profile and potentially allowing us to design a redoseable gene delivery vehicle.
scalable manufacturing
PDPs are readily-constructed in a bacterial cell line, allowing us to produce a clinical dose at >100X lower cost compared to AAV. This makes for a scalable and accessible genomic medicine for all.
PDP UNIQUE ADVANTAGE
gensaic is developing a proprietary RNA-driven directed evolution platform for the high-throughput screening of PDP variants. Using our platform, we can identify PDP variants capable of enhanced cell-specific internalization, intracellular trafficking, and efficient gene expression in human cells.
multi-dimensional directed evolution for gene expression